Protein and ligand novelty in drug–target interaction prediction: a dual-encoder fusion strategy for more interpretable and generalizable modeling

Predicting drug-target interactions (DTIs) is a fundamental task in computational drug discovery, where reliable generalization to novel compounds and protein targets is essential for practical virtual screening and drug repurposing. However, most deep learning models are evaluated using random or single-split settings that fail to reflect the ligand and protein novelty conditions encountered in real-world discovery pipelines. This work proposes a dual-encoder fusion framework for robust and interpretable DTI prediction. The model combines pretrained ESM protein embeddings with two complementary ligand representations: a ChemBERTa-based molecular language encoder and a graph-based structural encoder. Predictions from both branches are integrated through decision-level fusion. To rigorously evaluate generalization, we adopt a novelty-aware protocol that isolates ligand novelty, protein novelty, and their joint occurrence. A ligand-centered, gradientbased interpretability analysis is also employed to examine how molecular substructures contribute to binding predictions. Experiments on the largescale BindingDB dataset show that ligand novelty induces minimal performance degradation, with strong results under warm and cold-drug settings (F1 = 0.84-0.87; AUC = 0.87-0.89). In contrast, protein novelty emerges as the dominant generalization bottleneck, producing the largest performance drops under cold-protein and double-cold conditions. Across all scenarios, the fusion model exhibits the most stable behavior, achieving an AUC of 0.90 in the warm setting. External validation on the Davis and KIBA datasets further demonstrates consistent AUC values (0.60-0.64) and high recall despite substantial biochemical domain shift. These results highlight the importance of novelty-aware evaluation and show that decision-level fusion provides a practical pathway toward reliable and interpretable DTI prediction.

Authors

Institutions

Publication Details

Journal
BMC Bioinformatics
Published
2026-04-22
DOI
https://doi.org/10.1186/s12859-026-06457-5
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Protein and ligand novelty in drug–target interaction prediction: a dual-encoder fusion strategy for more interpretable and generalizable modeling

Khadidja Henni, Lina Abou-Abbas
BMC Bioinformatics
Computational Drug Discovery Methods
article

Protein and ligand novelty in drug–target interaction prediction: a dual-encoder fusion strategy for more interpretable and generalizable modeling

Khadidja Henni, Lina Abou-Abbas
article en

Abstract

Predicting drug-target interactions (DTIs) is a fundamental task in computational drug discovery, where reliable generalization to novel compounds and protein targets is essential for practical virtual screening and drug repurposing. However, most deep learning models are evaluated using random or single-split settings that fail to reflect the ligand and protein novelty conditions encountered in real-world discovery pipelines. This work proposes a dual-encoder fusion framework for robust and interpretable DTI prediction. The model combines pretrained ESM protein embeddings with two complementary ligand representations: a ChemBERTa-based molecular language encoder and a graph-based structural encoder. Predictions from both branches are integrated through decision-level fusion. To rigorously evaluate generalization, we adopt a novelty-aware protocol that isolates ligand novelty, protein novelty, and their joint occurrence. A ligand-centered, gradientbased interpretability analysis is also employed to examine how molecular substructures contribute to binding predictions. Experiments on the largescale BindingDB dataset show that ligand novelty induces minimal performance degradation, with strong results under warm and cold-drug settings (F1 = 0.84-0.87; AUC = 0.87-0.89). In contrast, protein novelty emerges as the dominant generalization bottleneck, producing the largest performance drops under cold-protein and double-cold conditions. Across all scenarios, the fusion model exhibits the most stable behavior, achieving an AUC of 0.90 in the warm setting. External validation on the Davis and KIBA datasets further demonstrates consistent AUC values (0.60-0.64) and high recall despite substantial biochemical domain shift. These results highlight the importance of novelty-aware evaluation and show that decision-level fusion provides a practical pathway toward reliable and interpretable DTI prediction.

BMC Bioinformatics
Université TÉLUQ (CA), Lebanese American University (LB)
Zero hunger
Openalex Percentile: Top 6%
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.